However, according to our systematic search, in patients with lung cancer, the effect of V2R antagonist treatment on mortality has only been evaluated in one study, which also demonstrated the cost-effectiveness of tolvaptan treatment in Swedish patients with SIADH in pneumonia or SCLC (79). This evidence concerns the gene AVPR2 and susceptibility to pneumonia measurement.